I liked the transparency
Diabetes Therapy, 12 (5), 13251339
e Information collected at screening on comorbidities was based on medical history and included: type 2 diabetes (STEP 2 only), dyslipidaemia, hypertension, coronary artery disease, cerebrovascular disease, obstructive sleep apnoea, impaired glucose metabolism (not included for STEP 2), reproductive system disorders, liver disease, kidney disease, osteoarthritis, gout, thyroid disease (STEP 3 only) and asthma or chronic obstructive pulmonary disease
While these agents are now recognized for their dual cardiometabolic and renal protective effects, earlier meta-analyses lacked dedicated renal outcome trials to fully assess their efficacy in high-risk CKD/CVD populations
JAMA 325 , 22042206 (2021)